Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer

被引:10
|
作者
Gupta, Swati [1 ]
Mani, Navin R. [1 ]
Carvajal-Hausdorf, Daniel E. [1 ,2 ]
Bossuyt, Veerle [1 ]
Ho, Kenneth [3 ]
Weidler, Jodi [4 ]
Wong, Wendy [3 ]
Rhees, Brian [3 ]
Bates, Michael [4 ]
Rimm, David L. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[2] Univ Desarrollo, Fac Med, Clin Alemana, Anat Patol, Santiago, Chile
[3] Cepheid, Div Oncol Res & Dev, Oncol, Sunnyvale, CA USA
[4] Cepheid, Med & Sci Affairs & Strategy, Oncol, Sunnyvale, CA USA
关键词
MESSENGER-RNA; IN-SITU; IMMUNOHISTOCHEMISTRY; CARCINOMA; TAMOXIFEN; ASSAY;
D O I
10.1038/s41374-018-0064-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An on-demand, closed RT-qPCR, the GeneXpert (GX) system, has the potential to provide biomarker information in low-resourced settings and elsewhere. We used this system with a research use only version of the Breast Cancer STRAT4 cartridge that measures the mRNA expression levels of ERBB2, ESR1, PGR, and MKi67. Here we evaluated the impact of non-macrodissected (non m-d) versus macrodissected (m-d) samples using STRAT4 on formalin-fixed, paraffin-embedded (FFPE) core needle biopsies. Two cohorts were assessed: (1) 60 FFPE infiltrating ductal carcinoma (IDCA) cases and (2) 20 FFPE IDCA cases with ductal carcinoma in situ (DCIS) with a range of HER2 expression as determined by clinical immunohistochemistry and fluorescence in situ hybridization (IHC/FISH). We observed about half of the core needle biopsy area as invasive tumor in both IDCA (mean = 51.5%) and IDCA with DCIS (mean = 53.5%) cohorts, but also found the mRNA levels were independent of tumor area. We found excellent agreement of the mRNA transcript level between the paired samples, m-d versus non m-d, for ERBB2, ESR1, PGR, and MKi67 for both the IDCA and IDCA with DCIS cohorts. No significant difference (P > 0.99) was observed when we compared the mRNA transcript level between the paired samples m-d versus non m-d. In addition, we noted a significant concordance (P < 0.001) between RT-qPCR and IHC/FISH for HER2-positivity, ER-positivity, and PR-positivity, independent of specimen dissection. These data suggest that mRNA expression for ERBB2, ESR, and PGR is sufficiently low in surrounding tissue cells such that macrodissection is not required for assessment of key breast cancer mRNA markers and is independent of the amount of input tumor. This approach may be valuable in settings lacking pathology expertise or using specimen types, such as fine-needle aspirates, where it may be challenging to separate non-tumor from tumor tissue.
引用
收藏
页码:1076 / 1083
页数:8
相关论文
共 50 条
  • [1] Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer
    Gupta, Swati
    Carvajal-Hausdorf, Daniel E.
    Wasserman, Brad E.
    Ho, Kenneth
    Weidler, Jodi
    Wong, Wendy
    Rhees, Brian
    Bates, Michael
    Rimm, David L.
    CANCER RESEARCH, 2018, 78 (04)
  • [2] High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence
    Wasserman, B.
    Carvajal-Hausdorf, D.
    Ho, K.
    Wong, W.
    Wu, N.
    Chu, V. C.
    Lai, E. W.
    Weidler, J. M.
    Bates, M.
    Neumenister, V.
    Rimm, D. L.
    CANCER RESEARCH, 2017, 77
  • [3] High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence
    Wasserman, Brad E.
    Carvajal-Hausdorf, Daniel E.
    Ho, Kenneth
    Wong, Wendy
    Wu, Natalie
    Chu, Victor C.
    Lai, Edwin W.
    Weidler, Jodi M.
    Bates, Michael
    Neumeister, Veronique
    Rimm, David L.
    LABORATORY INVESTIGATION, 2017, 97 (12) : 1521 - 1526
  • [4] Evaluation of RT-qPCR and luminex-based methodolgies in HER2 breast cancer testing
    Kornaga, Elizabeth N.
    McIntyre, John B.
    Klimowicz, Alexander C.
    Guggisberg, Natalia
    Morris, Don G.
    Magliocco, Anthony M.
    CANCER RESEARCH, 2015, 75
  • [5] Comparison of ER, PR, HER2 and Ki67 expression by MammaTyper® RT-qPCR and immunohistochemistry (IHC) on needle core biopsies of breast cancer
    Shaaban, A.
    Badr, N.
    Zaakouk, M.
    Kearns, D.
    Kong, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S87 - S88
  • [6] Breast Cancer with Equivocal HER2 IHC: Does HER2 IHC Intensity Identify Areas with FISH Amplification?
    Hertel, Johann D.
    Kaiser-Rogers, Kathleen
    O'Connor, Siobhan
    Calhoun, Benjamin
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 173 - 173
  • [7] Breast Cancer with Equivocal HER2 IHC: Does HER2 IHC Intensity Identify Areas with FISH Amplification?
    Hertel, Johann D.
    Kaiser-Rogers, Kathleen
    O'Connor, Siobhan
    Calhoun, Benjamin
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 173 - 173
  • [8] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
    Sahoo, Sunati
    Hwang, Helena
    CANCER RESEARCH, 2015, 75
  • [9] Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer
    El Hadi, Hicham
    Abdellaoui-Maane, Imane
    Kottwitz, Denise
    El Amrani, Manal
    Bouchoutrouch, Nadia
    Qmichou, Zineb
    Karkouri, Mehdi
    ElAttar, Hicham
    Errihani, Hassan
    Fernandez, Pedro L.
    Bakri, Youssef
    Sefrioui, Hassan
    Moumen, Abdeladim
    GENE, 2017, 605 : 114 - 122
  • [10] Comparison of HER2 Testing by IHC/FISH and RT-PCR in Estrogen Receptor (ER) Negative or Borderline Patients (pts) with Early Stage Breast Cancer (ESBC)
    Singh, B.
    Ziguridis, N.
    Butler, S.
    Jamshidian, F.
    Cherbavaz, D.
    Sing, A.
    MODERN PATHOLOGY, 2013, 26 : 70A - 70A